St. Jude Children's Research Hospital, Memphis, Tennessee.
College of Pharmacy, Chungbuk National University, Cheongju, Republic of South Korea.
Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2096-2104. doi: 10.1158/1055-9965.EPI-21-0448. Epub 2021 Aug 31.
Subsequent thyroid cancer (STC) is one of the most common malignancies in childhood cancer survivors. We aimed to evaluate the polygenic contributions to STC risk and potential utility in improving risk prediction.
A polygenic risk score (PRS) was calculated from 12 independent SNPs associated with thyroid cancer risk in the general population. Associations between PRS and STC risk were evaluated among survivors from St. Jude Lifetime Cohort (SJLIFE) and were replicated in survivors from Childhood Cancer Survivor Study (CCSS). A risk prediction model integrating the PRS and clinical factors, initially developed in SJLIFE, and its performance were validated in CCSS.
Among 2,370 SJLIFE survivors with a median follow-up of 28.8 [interquartile range (IQR) = 21.9-36.1] years, 65 (2.7%) developed STC. Among them, the standardized PRS was associated with an increased rate of STC [relative rate (RR) = 1.57; 95% confidence interval (CI) = 1.24-1.98; < 0.001]. Similar associations were replicated in 6,416 CCSS survivors, among whom 121 (1.9%) developed STC during median follow-up of 28.9 (IQR = 22.6-34.6) years (RR = 1.52; 95% CI = 1.25-1.83; < 0.001). A risk prediction model integrating the PRS with clinical factors showed better performance than the model considering only clinical factors in SJLIFE ( = 0.004, AUC = 83.2% vs. 82.1%, at age 40), which was further validated in CCSS ( = 0.010, AUC = 72.9% vs. 70.6%).
Integration of the PRS with clinical factors provided a statistically significant improvement in risk prediction of STC, although the magnitude of improvement was modest.
PRS improves risk stratification and prediction of STC, suggesting its potential utility for optimizing screening strategies in survivorship care.
继发甲状腺癌(STC)是儿童癌症幸存者中最常见的恶性肿瘤之一。我们旨在评估多基因对 STC 风险的贡献,并评估其在改善风险预测方面的潜在效用。
从与一般人群甲状腺癌风险相关的 12 个独立 SNP 中计算出多基因风险评分(PRS)。在圣裘德终身队列(SJLIFE)幸存者中评估 PRS 与 STC 风险之间的关联,并在儿童癌症幸存者研究(CCSS)幸存者中进行复制。最初在 SJLIFE 中开发的整合 PRS 和临床因素的风险预测模型及其性能在 CCSS 中进行了验证。
在中位随访时间为 28.8 岁(IQR=21.9-36.1)的 2370 名 SJLIFE 幸存者中,有 65 名(2.7%)发生了 STC。其中,标准化 PRS 与 STC 发生率的增加相关[相对风险(RR)=1.57;95%置信区间(CI)=1.24-1.98;<0.001]。在中位随访时间为 28.9 岁(IQR=22.6-34.6)的 6416 名 CCSS 幸存者中,也复制了类似的关联(RR=1.52;95%CI=1.25-1.83;<0.001)。将 PRS 与临床因素相结合的风险预测模型在 SJLIFE 中的表现优于仅考虑临床因素的模型(=0.004,AUC=83.2%vs.82.1%,在 40 岁时),在 CCSS 中进一步得到验证(=0.010,AUC=72.9%vs.70.6%)。
将 PRS 与临床因素相结合,在 STC 的风险预测方面提供了统计学上的显著改善,尽管改善的幅度不大。
PRS 提高了 STC 的风险分层和预测,表明其在生存护理中优化筛查策略方面具有潜在的效用。